IDEAS home Printed from https://ideas.repec.org/a/gam/jijerp/v19y2022i3p1879-d744183.html
   My bibliography  Save this article

The Role of Artificial Intelligence and Machine Learning Amid the COVID-19 Pandemic: What Lessons Are We Learning on 4IR and the Sustainable Development Goals

Author

Listed:
  • David Mhlanga

    (Faculty of Business and Economics, University of Johannesburg, Johannesburg 2006, South Africa)

Abstract

The COVID-19 pandemic came with disruptions in every aspect of human existence, with all the sectors of the economies of the world affected greatly. In the health sector, the pandemic halted and reversed progress in health and subsequently shortened life expectancy, especially in developing and underdeveloped nations. On the other hand, machine learning and artificial intelligence contributed a great deal to the handling of the pandemic globally. Therefore, the current study aimed to assess the role played by artificial intelligence and machine learning in addressing the dangers posed by the COVID-19 pandemic, as well as extrapolate the lessons on the fourth industrial revolution and sustainable development goals. Using qualitative content analysis, the results indicated that artificial intelligence and machine learning played an important role in the response to the challenges posed by the COVID-19 pandemic. Artificial intelligence, machine learning, and various digital communication tools through telehealth performed meaningful roles in scaling customer communications, provided a platform for understanding how COVID-19 spreads, and sped up research and treatment of COVID-19, among other notable achievements. The lessons we draw from this is that, despite the disruptions and the rise in the number of unintended consequences of technology in the fourth industrial revolution, the role played by artificial intelligence and machine learning motivates us to conclude that governments must build trust in these technologies, to address health problems going forward, to ensure that the sustainable development goals related to good health and wellbeing are achieved.

Suggested Citation

  • David Mhlanga, 2022. "The Role of Artificial Intelligence and Machine Learning Amid the COVID-19 Pandemic: What Lessons Are We Learning on 4IR and the Sustainable Development Goals," IJERPH, MDPI, vol. 19(3), pages 1-22, February.
    • Handle: RePEc:gam:jijerp:v:19:y:2022:i:3:p:1879-:d:744183
    as

    Download full text from publisher

    File URL: https://www.mdpi.com/1660-4601/19/3/1879/pdf
    Download Restriction: no
    File URL: https://www.mdpi.com/1660-4601/19/3/1879/
    Download Restriction: no
    ---><---

    References listed on IDEAS

    as
    1. DiMasi, Joseph A. & Grabowski, Henry G. & Hansen, Ronald W., 2016. "Innovation in the pharmaceutical industry: New estimates of R&D costs," Journal of Health Economics, Elsevier, vol. 47(C), pages 20-33.
    2. David Mhlanga & Rufaro Garidzirai, 2020. "The Influence of Racial Differences in the Demand for Healthcare in South Africa: A Case of Public Healthcare," IJERPH, MDPI, vol. 17(14), pages 1-10, July.
    Full references (including those not matched with items on IDEAS)

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. M. M. Kamruzzaman & Saad Alanazi & Madallah Alruwaili & Nasser Alshammari & Said Elaiwat & Marwan Abu-Zanona & Nisreen Innab & Bassam Mohammad Elzaghmouri & Bandar Ahmed Alanazi, 2023. "AI- and IoT-Assisted Sustainable Education Systems during Pandemics, such as COVID-19, for Smart Cities," Sustainability, MDPI, vol. 15(10), pages 1-17, May.
    2. Yeguan Yu, 2023. "The Impact of Financial System on Carbon Intensity: From the Perspective of Digitalization," Sustainability, MDPI, vol. 15(2), pages 1-22, January.
    3. David Mhlanga, 2023. "Artificial Intelligence and Machine Learning for Energy Consumption and Production in Emerging Markets: A Review," Energies, MDPI, vol. 16(2), pages 1-17, January.

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Dosis, Anastasios & Muthoo, Abhinay, 2019. "Experimentation in Dynamic R&D Competition," CRETA Online Discussion Paper Series 52, Centre for Research in Economic Theory and its Applications CRETA.
    2. Yusuke Oh & Koji Takahashi, 2020. "R&D and Innovation: Evidence from Patent Data," Bank of Japan Working Paper Series 20-E-7, Bank of Japan.
    3. Gamba, Simona & Magazzini, Laura & Pertile, Paolo, 2021. "R&D and market size: Who benefits from orphan drug legislation?," Journal of Health Economics, Elsevier, vol. 80(C).
    4. Branstetter, Lee & Chatterjee, Chirantan & Higgins, Matthew J., 2022. "Generic competition and the incentives for early-stage pharmaceutical innovation," Research Policy, Elsevier, vol. 51(10).
    5. Alfred B. Ordman, 2022. "When Will the FDA Do What Is in People’s Best Interests?," American Journal of Economics and Sociology, Wiley Blackwell, vol. 81(4), pages 721-751, September.
    6. Edouard Debonneuil & Anne Eyraud-Loisel & Frédéric Planchet, 2018. "Can Pension Funds Partially Manage Longevity Risk by Investing in a Longevity Megafund?," Risks, MDPI, vol. 6(3), pages 1-27, July.
    7. Billette de Villemeur, Etienne & Versaevel, Bruno, 2019. "One lab, two firms, many possibilities: On R&D outsourcing in the biopharmaceutical industry," Journal of Health Economics, Elsevier, vol. 65(C), pages 260-283.
    8. Fabian Gaessler & Stefan Wagner, 2022. "Patents, Data Exclusivity, and the Development of New Drugs," The Review of Economics and Statistics, MIT Press, vol. 104(3), pages 571-586, May.
    9. Gregor Dorfleitner & Felix Rößle, 2018. "The financial performance of the health care industry: a global, regional and industry specific empirical investigation," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 19(4), pages 585-594, May.
    10. Farasat A. S. Bokhari & Franco Mariuzzo & Anna Rita Bennato, 2021. "Innovation and growth in the UK pharmaceuticals: the case of product and marketing introductions," Small Business Economics, Springer, vol. 57(1), pages 603-634, June.
    11. Stig Johan Wiklund, 2019. "A modelling framework for improved design and decision-making in drug development," PLOS ONE, Public Library of Science, vol. 14(8), pages 1-22, August.
    12. Yin, Nina, 2023. "Pharmaceuticals, incremental innovation and market exclusivity," International Journal of Industrial Organization, Elsevier, vol. 87(C).
    13. Heyoung Yang & Hyuck Jai Lee, 2018. "Long-Term Collaboration Network Based on ClinicalTrials.gov Database in the Pharmaceutical Industry," Sustainability, MDPI, vol. 10(2), pages 1-14, January.
    14. Ralph Siebert & Zhili Tian, 2020. "Dynamic Mergers Effects on R&D Investments and Drug Development across Research Phases in the Pharmaceutical Industry," CESifo Working Paper Series 8303, CESifo.
    15. Stacy Sneeringer & Matt Clancy, 2020. "Incentivizing New Veterinary Pharmaceutical Products to Combat Antibiotic Resistance," Applied Economic Perspectives and Policy, John Wiley & Sons, vol. 42(4), pages 653-673, December.
    16. Gemma Turon & Jason Hlozek & John G. Woodland & Ankur Kumar & Kelly Chibale & Miquel Duran-Frigola, 2023. "First fully-automated AI/ML virtual screening cascade implemented at a drug discovery centre in Africa," Nature Communications, Nature, vol. 14(1), pages 1-11, December.
    17. Adrian Towse;Jimena Ferraro;Jorge Mestre-Ferrandiz, 2017. "Incentives for New Drugs to Tackle Anti-Microbial Resistance," Briefing 001842, Office of Health Economics.
    18. Steffen Nauhaus & Johannes Luger & Sebastian Raisch, 2021. "Strategic Decision Making in the Digital Age: Expert Sentiment and Corporate Capital Allocation," Journal of Management Studies, Wiley Blackwell, vol. 58(7), pages 1933-1961, November.
    19. Abdulaziz Hamid & Aprill Z. Dawson & Yilin Xu & Leonard E. Egede, 2024. "Independent Correlates of Glycemic Control among Adults with Diabetes in South Africa," IJERPH, MDPI, vol. 21(4), pages 1-12, April.
    20. Daniel Tobias Michaeli & Hasan Basri Yagmur & Timur Achmadeev & Thomas Michaeli, 2022. "Value drivers of development stage biopharma companies," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 23(8), pages 1287-1296, November.

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:gam:jijerp:v:19:y:2022:i:3:p:1879-:d:744183. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: MDPI Indexing Manager (email available below). General contact details of provider: https://www.mdpi.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.